Eccrine squamous syringometaplasia associated with vemurafenib therapy

Journal of the American Academy of Dermatology

Volumn 67, Issue 5, 2012, Pages e208-e210

  Story, Scott G ^a   Beschloss, Jonathan K ^b   Dolan, Christopher K ^b   Thomas, Brian C ^b  

^a Uniformed Services University of the Health Sciences   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE; VEMURAFENIB;

AGED; CASE REPORT; CHEMICALLY INDUCED DISORDER; DERMIS; DRUG ERUPTION; ERYTHEMA; FEMALE; HUMAN; LETTER; MELANOMA; METAPLASIA; PATHOLOGY; SKIN TUMOR; SWEAT GLAND; SWEAT GLAND TUMOR; SYRINGOMA;

AGED; ANTINEOPLASTIC AGENTS; DERMIS; DRUG ERUPTIONS; ECCRINE GLANDS; ERYTHEMA; FEMALE; HUMANS; INDOLES; MELANOMA; METAPLASIA; SKIN NEOPLASMS; SULFONAMIDES; SWEAT GLAND NEOPLASMS; SYRINGOMA;

EID: 84872685258     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.02.038     Document Type: Article

References (5)

1. Bolognia J, Cooper D, Glusac E. Toxic erythema of chemotherapy: A useful clinical term. J Am Acad Dermatol 2008;59: 524-9
2. Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
3. Martorell-Calatayud A, Sanmartin O, Botella-Estrada R, Balmer N, Serra-Guillen C, Gomez-Moyano E, et al. Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: Reappraisal of epidemiological, clinical, and pathologic features. J Am Acad Dermatol 2011;64:1092-103
4. Van de Voorde K, De Raeve H, Van Regenmortel N, Lambert J. Imatinib-induced eccrine squamous syringometaplasia. J Am Acad Dermatol 2006;55:S58-9
5. Sheen Y, Huang C, Chu C. Eccrine squamous syringometaplasia associated with suntinib therapy. Eur Acad Dermatol Venereol 2007;21:1136-7.